The Chemours Company (NYSE:CC) Receives $23.75 Consensus PT from Analysts

Shares of The Chemours Company (NYSE:CC) have earned an average recommendation of “Hold” from the eight research firms that are presently covering the stock, MarketBeat Ratings reports. Five equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $23.75.

Several brokerages recently issued reports on CC. Morgan Stanley reduced their price objective on Chemours from $25.00 to $22.00 and set an “equal weight” rating for the company in a report on Monday, January 13th. Mizuho reduced their price objective on Chemours from $22.00 to $21.00 and set a “neutral” rating for the company in a report on Tuesday, January 7th. Barclays lifted their price objective on Chemours from $21.00 to $23.00 and gave the stock an “equal weight” rating in a report on Tuesday, November 5th. The Goldman Sachs Group reduced their price objective on Chemours from $24.00 to $21.00 and set a “neutral” rating for the company in a report on Tuesday, January 7th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $25.00 price objective on shares of Chemours in a report on Thursday, December 12th.

Chemours Trading Down 1.6 %

NYSE:CC opened at $19.68 on Thursday. The stock’s 50 day moving average price is $19.18 and its 200 day moving average price is $19.65. The company has a market capitalization of $2.94 billion, a PE ratio of 39.35 and a beta of 1.83. The company has a quick ratio of 0.92, a current ratio of 1.73 and a debt-to-equity ratio of 6.05. Chemours has a 52-week low of $15.10 and a 52-week high of $32.25.

Chemours (NYSE:CC) last announced its earnings results on Monday, November 4th. The specialty chemicals company reported $0.40 earnings per share for the quarter, beating the consensus estimate of $0.32 by $0.08. Chemours had a return on equity of 29.48% and a net margin of 1.34%. The company had revenue of $1.50 billion for the quarter, compared to the consensus estimate of $1.44 billion. During the same period last year, the business posted $0.64 EPS. The company’s revenue was up .9% on a year-over-year basis. On average, research analysts anticipate that Chemours will post 1.19 EPS for the current year.

Insider Transactions at Chemours

In other news, SVP Alvenia Scarborough sold 7,500 shares of Chemours stock in a transaction dated Thursday, November 7th. The stock was sold at an average price of $20.64, for a total value of $154,800.00. Following the transaction, the senior vice president now directly owns 16,645 shares in the company, valued at approximately $343,552.80. The trade was a 31.06 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 0.47% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Chemours

A number of institutional investors have recently added to or reduced their stakes in the company. EMC Capital Management boosted its holdings in shares of Chemours by 74.6% in the 4th quarter. EMC Capital Management now owns 9,534 shares of the specialty chemicals company’s stock worth $161,000 after acquiring an additional 4,073 shares in the last quarter. Twelve Points Wealth Management LLC increased its position in shares of Chemours by 42.8% in the 4th quarter. Twelve Points Wealth Management LLC now owns 78,325 shares of the specialty chemicals company’s stock valued at $1,324,000 after buying an additional 23,490 shares in the last quarter. KBC Group NV boosted its stake in Chemours by 38.2% in the 4th quarter. KBC Group NV now owns 6,176 shares of the specialty chemicals company’s stock worth $104,000 after purchasing an additional 1,708 shares during the period. Inspire Investing LLC boosted its stake in Chemours by 17.4% in the 4th quarter. Inspire Investing LLC now owns 23,799 shares of the specialty chemicals company’s stock worth $402,000 after purchasing an additional 3,523 shares during the period. Finally, Matrix Trust Co boosted its stake in shares of Chemours by 715.7% during the 4th quarter. Matrix Trust Co now owns 9,952 shares of the specialty chemicals company’s stock worth $168,000 after buying an additional 8,732 shares during the last quarter. 76.26% of the stock is owned by institutional investors and hedge funds.

About Chemours

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.